---
title: "AthenaBIO (formerly AthenaDAO)"
url: "https://caper.network/wiki/desci/ecosystem/athenadao"
updated: 2026-08-22
last_verified: 2026-08-01
license: CC-BY-4.0
license_url: "https://creativecommons.org/licenses/by/4.0/"
---

# AthenaBIO (formerly AthenaDAO)

|  |  |
| --- | --- |
| **Type** | DeSci organization — women's health R&D |
| **Founded** | 2022, as AthenaDAO |
| **Renamed** | AthenaBIO, announced 8 March 2026 |
| **Founder** | Laura Minquini |
| **Focus** | Women's health research funding & IP |
| **Ecosystem** | [Bio Protocol](/wiki/desci/ecosystem/bio-xyz) BioDAO |
| **Token** | ATH (still live post-rename) |
| **Capital vehicle** | Holding company + SPVs, ~$5M target, ~15 assets |
| **Deployed to date** | ~$1.5M across five review cohorts |
| **Chain** | Ethereum |
| **Governance** | Snapshot [athenadao.eth](https://snapshot.box/#/s:athenadao.eth); 18 proposals, all cleared quorum; proposal creation restricted to 5 allowlisted addresses; **silent since 3 Sep 2025** |
| **Status** | Active as an organization – newsletter published 30 July 2026 – but its DAO governance is dormant |
| **Website** | [athenadao.co](https://www.athenadao.co) |

## Overview

**AthenaBIO**, founded in 2022 as **AthenaDAO**, is a [decentralized science (DeSci)](/wiki/desci/what-is-desci) organization that sources, funds and incubates women's health R&D, connecting researchers with legal, strategic, scientific and market support. It began as a [Bio Protocol](/wiki/desci/ecosystem/bio-xyz) BioDAO, using community-held tokens to govern which projects get funded and how the resulting intellectual property is stewarded, and it still describes its funding rails in those terms — [“on-chain transparent blockchain technology and incentives to fund early-stage research and biotech startups via a token held by the community”](https://www.athenadao.co), with capital allocation done collaboratively.

Women's health is chronically under-funded relative to its disease burden, and the organization frames the gap as [a market opportunity rather than a charity case](https://beautymatter.com/articles/how-athena-bio-is-rewriting-rd-funding-for-womens-health) — pooling community capital to de-risk early translational science that traditional grant pipelines and venture funds routinely skip. Its named research bets concentrate on ovarian aging: novel therapeutic targets with the AI drug-discovery firm Gero, the integrated stress response (ISR) pathway for ovarian follicle survival, and the cGAS–STING inflammatory pathway in reproductive aging.

## From AthenaDAO to AthenaBIO

On **8 March 2026** the organization published [“AthenaBIO: The first Science-First Ecosystem for Women's Health R&D”](https://athenadao.substack.com/p/athenabio-the-first-science-first), which introduces the entity as _“AthenaBIO (formerly known as AthenaDAO)”_. The rename has since propagated through the public site: [athenadao.co](https://www.athenadao.co) now reads “AthenaBIO” in its body copy and footer while keeping the original domain, and the organization describes itself as **“a think tank and global community of researchers, funders, and advocates”** rather than as a DAO. The ATH token and the community-allocation framing remain on the site.

The rename formalises a shift that began in September 2025, when AthenaDAO [launched AthenaBIO](https://athenadao.substack.com/p/athenabio) as an equity vehicle to carry vetted assets through the capital-intensive phases — validation, regulation, scale — that a community treasury alone cannot underwrite. It is structured as [a holding company with SPVs rather than a traditional closed-end fund](https://beautymatter.com/articles/how-athena-bio-is-rewriting-rd-funding-for-womens-health), aiming to raise about **$5 million** against roughly **15 early-stage assets** across AI-driven diagnostics, ovarian health and reproductive technology, all previously cleared by the organization's scientific review.

The founders were candid about the motive: as one put it, “your token is never going to reflect the value of what you are building” — a recurring tension in [DAO tokenomics](/wiki/dao-governance/concepts/treasury/dao-tokenomics), where a freely-traded governance token's price drifts away from the value of the underlying work. The answer here was to split the two rather than pick one: keep the community layer for sourcing, education and IP governance, and route institutional capital through a separate equity structure. It is worth reading alongside [VitaDAO](/wiki/desci/ecosystem/vitadao), which met the same discovery-to-commercialization gap by pairing IP-NFTs with a pharma spinout instead of a holding company.

## Funding model & track record

Through five review cohorts the organization's community has [deployed roughly $1.5 million into science](https://www.futurefemhealth.com/p/exclusive-new-5m-athenabio-vehicle). Its own March 2026 count of what that bought is **six labs, 20 academic fellowships, three pre-prints, three start-ups, one summit and more than 100 live events**, from a Science & Deal Flow team that reports having [evaluated over 430 scientific proposals across five focused cohorts](https://athenadao.substack.com/p/athenabio-the-first-science-first). These are self-reported figures and the counts differ slightly between the organization's own posts and press coverage; treat them as an order of magnitude rather than an audited ledger.

Every asset passes the scientific-review process before capital is committed, and funded IP is held and licensed through the [IP-NFT](/wiki/desci/ip-nfts) tooling built by [Molecule](/wiki/desci/ecosystem/molecule) — the same rails used by [HairDAO](/wiki/desci/ecosystem/hairdao) and the rest of the Bio Protocol cohort. The community layer also publishes standalone research: a data-and-wearables report on the ownership and governance of women's health data sits alongside the funded science, and the newsletter has continued to publish through **July 2026**, which is the clearest available signal that the organization is operating rather than winding down.

## The governance record, and when it stopped

AthenaDAO's binding votes ran on Snapshot at [athenadao.eth](https://snapshot.box/#/s:athenadao.eth), and the space is still readable in full whatever the organization now calls itself. It carried **18 proposals** between October 2023 and September 2025, and every one of them cleared quorum – the first three against quorums of 25,000 and 250,000 ATH, the remaining fifteen against 390,646 ATH, with weight cast ranging from 213,352 to 1,857,921 ATH. Head-count turnout never exceeded 18 voters. On the measure most DAOs fail, this one did not fail once.

It stopped anyway, and the sequence is tight. [ADP-013](https://snapshot.box/#/s:athenadao.eth/proposal/0xdd82af00f52481d1ebf25f96ef6f1267ee77772fa73db0d53826542aeef40e4a), funding a multi-hop RAG system for reproductive longevity with CoopHive, closed on **3 September 2025** with 1,857,921 ATH For, zero Against and zero Abstain from nine voters – the largest weight the space ever recorded, cast on its final proposal. Two weeks later, on 17 September 2025, the organization [announced AthenaBIO](https://athenadao.substack.com/p/athenabio) as the equity vehicle described above. The rename followed on 8 March 2026. As of 18 August 2026 the space has been silent for **349 days**.

Why no member restarted it is a setting rather than an attitude. The space restricts proposal creation to an author allowlist – one admin and four members, five addresses in total – which Snapshot documents as restricting proposals [“to authors only”](https://docs.snapshot.box/user-guides/spaces/settings) instead of validating a proposer's voting power against a threshold. ATH confers the right to vote and not the right to propose, so when the five stopped proposing there was no route by which a holder could put anything to the vote. This wiki treats that as a distinct class of [proposal throttle](/wiki/dao-governance/concepts/voting/proposal-throttles-and-rate-limits), and AthenaDAO is one of ten DeSci spaces measured there using it.

The token outlived the governance, which is the ordinary outcome rather than a surprising one. ATH's Ethereum contract, [0xA4ff…4739](https://etherscan.io/token/0xA4fFdf3208F46898CE063e25c1C43056FA754739), returns a `totalSupply` of exactly 30,000,000 with the symbol `ATH`; a second ATH contract on [Base](https://basescan.org/token/0x58D75a1c4477914f9a98A8708fEaeD1DbE40b8a3) holds 739,944.57, the Base-side balance behind the Aerodrome liquidity ADP-005 and ADP-008 incentivised, and the Snapshot space's two [token-weighted](/wiki/dao-governance/concepts/voting/token-weighted-voting) strategies sum a holder's balance across both chains. All four figures were read on-chain on 18 August 2026. What no longer exists is anything for that weight to be cast on.

## How Caper approaches this

The token-versus-equity split AthenaBIO reached for is exactly the seam a [caper](/wiki/foundations/what-is-a-caper) is designed to close. On Caper, contributed capital flows into the caper's own [bonding-curve](/wiki/markets/bonding-curve) treasury rather than into a free-floating token whose price detaches from the work — value accrues to the treasury itself, and members hold a [participation-weighted exit claim](/wiki/dao-governance/concepts/membership/rage-quit-and-exit-rights) on it. Research spending is then authorised the same way governance authorises any spend: a [PAYOUT proposal](/wiki/governance/proposals) that transfers a chosen currency and amount from the treasury to a lab or researcher once members [vote it through](/wiki/governance/voting). There is no separate equity vehicle to spin up, and voting weight is stake weighted by participation, so the people funding the science keep governance coupled to their exposure.

## External links

- [AthenaBIO — official website](https://www.athenadao.co)
- [“AthenaBIO: The first Science-First Ecosystem” — rename announcement, 8 March 2026](https://athenadao.substack.com/p/athenabio-the-first-science-first)
- [AthenaBIO launch — AthenaDAO Substack, September 2025](https://athenadao.substack.com/p/athenabio)
- [BeautyMatter — how AthenaBIO is rewriting R&D funding for women's health (January 2026)](https://beautymatter.com/articles/how-athena-bio-is-rewriting-rd-funding-for-womens-health)
- [Bio Protocol ecosystem](https://www.bio.xyz)